Inflammatory cytokines synergize with the HIV-1 Tat protein to promote angiogenesis and Kaposi's sarcoma via induction of basic fibroblast growth factor and the alpha(v)beta(3)
G. Barillari et al., Inflammatory cytokines synergize with the HIV-1 Tat protein to promote angiogenesis and Kaposi's sarcoma via induction of basic fibroblast growth factor and the alpha(v)beta(3), J IMMUNOL, 163(4), 1999, pp. 1929-1935
The Tat protein of HIV-1, a transactivator of viral gene expression, is rel
eased by acutely infected T tells and, in this form, exerts angiogenic acti
vities. These have linked the protein to the pathogenesis of Kaposi's sarco
ma (KS), a vascular tumor frequent and aggressive in HIV-1-infected individ
uals (AIDS-KS), In this study, we show that a combination of the same infla
mmatory cytokines increased in KS lesions, namely IL-1 beta, TNF-alpha, and
IFN-gamma, synergizes with Tat to promote in nude mice the development of
angioproliferative KS-like lesions that are not observed with each factor a
lone. Inflammatory cytokines induce the tissue expression of both basic fib
roblast growth factor (bFGF) and vascular endothelial growth factor (VEGF),
two angiogenic molecules highly produced in primary KS lesions. However, b
FGF, but not VEGF, synergizes with Tat in vivo and induces endothelial cell
s to migrate, to adhere, and to grow in response to Tat in vitro. Tar angio
genic effects correlate with the expression of the alpha(v)beta(3) integrin
that is induced by bFGF and binds the arginine-glycine-aspartic acid (RGD)
region of Tat, In contrast, no correlation is observed with the expression
of alpha(v)beta(5), which is promoted by VEGF and binds Tat basic region.
Finally, KS lesion formation induced by bFGF and Tat in nude mice is blocke
d by antagonists of RGD-binding integrins. Because alpha(v)beta(3) is an RG
D-binding integrin that is highly expressed in primary KS lesions, where it
colocalizes with extracellular Tat on vessels and spindle cells, these res
ults suggest that alpha(v)beta(3) competitors may represent a new strategy
for the treatment of AIDS-KS.